Nevirapine (NVP) is globally effective in combination treatment of HIV. Its current use in first line therapy is limited by severe immune-mediated adverse drug reactions (IM-ADRs) that significantly adversely impact patient outcome and healthcare costs. Distinct clinical phenotypes of NVP IM-ADRs include Stevens-Johnson Syndrome/Toxic epidermal necrolysis (SJS/TEN) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). DRESS is dependent on both CD4+ and CD8+ T cells and is characterized by fever, rash, hepatitis and eosinophilia. SJS/TEN is a human leukocyte antigen (HLA) class I restricted, CD8+ T-cell dependent hypersensitivity syndrome, which presents as a severe blistering skin rash that can lead to extensive and life-threatening epidermal necrosis. SJS/TEN is the severest IM-ADR and is complicated by a 50% age-dependent mortality rate and severe long-term morbidity in survivors. Pure T-cell mediated ADRs are strongly associated with genetic variation in HLA loci which has led to successful preventive genetic screening such as HLA-B*15:02 screening to prevent carbamazepine SJS/TEN. Current information on key risk HLA alleles specifically associated with NVP IM-ADRs across diverse populations in Africa and Asia is lacking. We have recently identified HLA-C*04:01 as a significant class I risk allele in South African HIV+ patients with NVP SJS/TEN. Another key unanswered question central to the mechanism of HLA-associated IM-ADRs is why hypersensitivity generally occurs in only a small proportion of those carrying an HLA-risk allele. We hypothesize that the immunophenotypic characterization and T-cell receptor (TCR) specificities of the drug- specific T cells in NVP IM-ADR patients will help answer this question. To facilitate the study of IM-ADRs, our research group has established global collaborations that have led to accrual of one of the largest international biobanks of PBMCs, blister fluid and skin biopsies from patients with T-cell mediated ADRs.
In Aim 1, I will immunophenotype the specific T cells responsible for NVP SJS/TEN in patients carrying a defined risk allele. I will characterize these NVP-responsive cells based on their cytokine outputs and cell surface and activation markers using enzyme-linked immunospot (ELISpot) assays and flow cytometry respectively.
In Aim 2, I will use ELISpot and flow cytometry to characterize the NVP-responsive T cells implicated in NVP DRESS. Finally in Aim 3, I will use single cell TCR sequencing, a Jurkat TCR reporter assay and droplet digital PCR, to identify and confirm the TCR specificities of the T-cell repertoire in patients with NVP IM-ADRs. Our proposed work will leverage clinical and immunologic approaches to define the immunopathogenesis of two distinct cutaneous NVP IM-ADR phenotypes. It is expected that these approaches will ultimately lead to translational outputs such as a sensitive predictive assay to identify the dominant cross-reactive TCRs in the peripheral blood of patients who are destined to develop NVP IM-ADRs. This research will provide the foundation to study the immunopathogenesis of other IM-ADRs and provide a roadmap for their preclinical prediction and prevention.

Public Health Relevance

Nevirapine (NVP), a drug used globally to treat human immunodeficiency virus (HIV), is associated with severe hypersensitivity reactions in a subset of patients. These immune-mediated adverse drug reactions (IM-ADRs) are a source of major burden to patients, the healthcare system and drug development. This study aims to define the immunopathogenesis of two distinct cutaneous NVP IM-ADR phenotypes with the goal of establishing future predictive tests to identify those at risk for HLA-restricted disease.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Individual Predoctoral NRSA for M.D./Ph.D. Fellowships (ADAMHA) (F30)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-F17-M (20)L)
Program Officer
Gondre-Lewis, Timothy A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Vanderbilt University Medical Center
Other Health Professions
Schools of Medicine
United States
Zip Code
Trubiano, Jason A; Strautins, Kaija; Redwood, Alec J et al. (2018) The Combined Utility of Ex Vivo IFN-? Release Enzyme-Linked ImmunoSpot Assay and In Vivo Skin Testing in Patients with Antibiotic-Associated Severe Cutaneous Adverse Reactions. J Allergy Clin Immunol Pract 6:1287-1296.e1
Peter, Jonathan Grant; Lehloenya, Rannakoe; Dlamini, Sipho et al. (2017) Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice. J Allergy Clin Immunol Pract 5:547-563